Your browser does not support JavaScript!

Interprotein Corporation discovers innovative therapeutics, which modulate Protein-Protein Interaction (PPI), in order to improve the lives of patients suffering from serious diseases

Interprotein Corporation, a Japanese drug discovery company, has a strategic focus on cutting edge technologies, knowhow, and valuable tools in order to identify strong affinity and compatibility to high-valued PPI targets. Interprotein has a strong portfolio including cytokine inhibitors, immune checkpoint inhibitors, Runx-1 inhibitor, Notch1 inhibitor, IgE inhibitor, and several novel PPI targets for rare diseases using two cutting edge technologies, INTENDD® (drug discovery strategy for small molecules) and helix-loop-helix peptide (HLHP) for middle-sized drug discovery.  Interprotein firmly believes that their drug discovery program can revolutionize unmet medical needs.

What's New

Apr.25,2016Interprotein Corporation and A.I. Squared, Inc. Sign a Joint Research and Development AI Drug Discovery Agreement
Nov.19,2015Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology
May.05,2015Masto Hosoda, CEO&PRESIDENT, gave a keynote lecture on SPACE PROTEIN Project Kickoff Symposium.
Dec.15,2014Adoption of the subject that Interprotein has applied as a subject for A-STEP
Mar.20,2014Participation of Interprotein in the space experiment for generation of high-quality protein crystals in "Kibo"
Nov.25,2013Adoption of conformationally-constrained peptide (MicroAntibody) binding to vascular endothelial growth factor (VEGF) as a subject for A-STEP